Treace Announces First Surgical Cases Utilizing the SpeedPlate™ MicroQuad™ Implant
Treace Medical Concepts (NASDAQ: TMCI) has announced the successful completion of first surgical cases using their new SpeedPlate™ MicroQuad™ implants. This innovation expands their SpeedPlate™ platform, designed for fast titanium compression fixation in bunion and midfoot deformity treatments.
The MicroQuad™ implant features an anatomic design with multiple fixation points on each joint side, delivering dynamic compression with rotational stability through a one-inch incision. The company plans a full market release in the first half of 2025. Initial surgical cases were performed by Dr. William T. DeCarbo, who praised the implant's anatomic contour and rotational stability through minimal incision.
Treace Medical Concepts (NASDAQ: TMCI) ha annunciato il completamento con successo dei primi interventi chirurgici utilizzando i nuovi impianti SpeedPlate™ MicroQuad™. Questa innovazione espande la loro piattaforma SpeedPlate™, progettata per una rapida fissazione in compressione in titanio per i trattamenti di alluce valgo e deformità del mesopiede.
l'impianto MicroQuad™ presenta un design anatomico con molteplici punti di fissaggio su ciascun lato dell'articolazione, offrendo compressione dinamica con stabilità rotazionale tramite un'incisione di un pollice. L'azienda prevede un lancio completo sul mercato nella prima metà del 2025. I primi casi chirurgici sono stati eseguiti dal Dr. William T. DeCarbo, che ha elogiato il contorno anatomico dell'impianto e la stabilità rotazionale attraverso un'incisione minima.
Treace Medical Concepts (NASDAQ: TMCI) ha anunciado la exitosa finalización de los primeros casos quirúrgicos utilizando sus nuevos implantes SpeedPlate™ MicroQuad™. Esta innovación expande su plataforma SpeedPlate™, diseñada para una rápida fijación en compresión de titanio en tratamientos de juanetes y deformidades de mediopié.
El implante MicroQuad™ cuenta con un diseño anatómico con múltiples puntos de fijación en cada lado de la articulación, proporcionando compresión dinámica con estabilidad rotacional a través de una incisión de una pulgada. La compañía planea un lanzamiento completo en el mercado en la primera mitad de 2025. Los primeros casos quirúrgicos fueron realizados por el Dr. William T. DeCarbo, quien elogió el contorno anatómico del implante y la estabilidad rotacional a través de una incisión mínima.
Treace Medical Concepts (NASDAQ: TMCI)는 새로운 SpeedPlate™ MicroQuad™ 임플란트를 사용한 첫 번째 수술 사례의 성공적인 완료를 발표했습니다. 이 혁신은 빠른 티타늄 압축 고정을 위한 SpeedPlate™ 플랫폼을 확장하여, 환부의 굴곡 및 중족골 변형 치료에 사용됩니다.
MicroQuad™ 임플란트는 각 관절 측면에 여러 고정점이 있는 해부학적 설계를 갖추고 있으며, 1인치 절개를 통해 회전 안정성을 제공하면서 동적 압축을 제공합니다. 이 회사는 2025년 상반기 안에 시장에서 전면 출시할 계획입니다. 초기 수술 사례는 William T. DeCarbo 박사에 의해 수행되었으며, 그는 최소 절개로 해부학적 윤곽과 회전 안정성을 칭찬했습니다.
Treace Medical Concepts (NASDAQ: TMCI) a annoncé l'achèvement réussi des premiers cas chirurgicaux utilisant leurs nouveaux implants SpeedPlate™ MicroQuad™. Cette innovation élargit leur plateforme SpeedPlate™, conçue pour une fixation en compression rapide en titane dans le traitement des oignons et des déformations du médio-pied.
L'implant MicroQuad™ présente un design anatomique avec plusieurs points de fixation de chaque côté de l'articulation, offrant une compression dynamique avec une stabilité rotationnelle à travers une incision d'un pouce. La société prévoit un lancement complet sur le marché au cours de la première moitié de 2025. Les premiers cas chirurgicaux ont été réalisés par le Dr William T. DeCarbo, qui a salué le contour anatomique de l'implant et la stabilité rotationnelle résultant d'une incision minimale.
Treace Medical Concepts (NASDAQ: TMCI) hat den erfolgreichen Abschluss der ersten chirurgischen Fälle mit ihren neuen SpeedPlate™ MicroQuad™ Implantaten bekannt gegeben. Diese Innovation erweitert ihre SpeedPlate™ Plattform, die für die schnelle titangestützte Kompressionsfixation bei Hallux Valgus und Mittelfußdeformitäten entwickelt wurde.
Das MicroQuad™ Implantat verfügt über ein anatomisches Design mit mehreren Fixierungspunkten an jeder Gelenkseite, das dynamische Kompression mit rotationaler Stabilität durch einen 1-Zoll-Schnitt bietet. Das Unternehmen plant eine vollständige Markteinführung in der ersten Hälfte von 2025. Die ersten chirurgischen Eingriffe wurden von Dr. William T. DeCarbo durchgeführt, der die anatomische Form und die rotatorische Stabilität des Implantats bei minimalem Schnitt lobte.
- New product launch expanding existing SpeedPlate™ platform
- Successful completion of first surgical cases with new implant
- Planned full market release in H1 2025
- Product compatible with minimally invasive surgical techniques
- None.
Insights
PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants.
The MicroQuad™ implant expands upon the broad utility of the SpeedPlate™ platform, which is designed for fast titanium compression fixation. The MicroQuad™ implant has a unique anatomic design with multiple points of fixation on each side of the joint to deliver dynamic compression with rotational stability through a one-inch incision for compatibility with minimally invasive techniques.
“The MicroQuad™ implant builds on the success of our proprietary SpeedPlate™ technology to provide a highly differentiated solution for fast, stable fixation designed to meet the growing surgeon and patient demand for minimally invasive Lapiplasty® and Adductoplasty® approaches,” said John T. Treace, CEO, Founder and Board Member of Treace. “We look forward to further expanding surgeon access to the MicroQuad™ implant as we move into full market release within the first half of 2025.”
William T. DeCarbo, DPM, of Greater Pittsburgh Foot & Ankle Center and a member of Treace’s Surgeon Advisory Board, who performed initial cases with the SpeedPlate™ MicroQuad™ implant, commented, “The MicroQuad™ implant takes the SpeedPlate™ system to a new level with an anatomic contour and additional rotational stability that gives me the clinical confidence I can deliver robust fixation through a small incision that patients desire.”
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s expectations of the timing for surgeon access to the MicroQuad™ implant and growth in surgeon and patient demand for minimally invasive Lapiplasty® and Adductoplasty® approaches. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether because of any new information, future developments or otherwise.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
Dr. DeCarbo is a paid consultant of the Company.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
When will Treace Medical (TMCI) release the SpeedPlate™ MicroQuad™ implant to full market?
What are the key features of TMCI's new SpeedPlate™ MicroQuad™ implant?
How does the new TMCI MicroQuad™ implant benefit patients?
What surgical procedures can TMCI's SpeedPlate™ MicroQuad™ implant be used for?
